Dimethyl Sulfoxide
Medchemexpress LLC Dm4 Solution 10Mm1Ml In Dmso | HY-12454-10MM1ML/DMSO SOL
Dm4 Solution 10Mm1Ml In Dmso
eMolecules 2168-93-6 | n-Butyl sulfoxide | Oakwood Chemicals | MFCD00002093 | 162.290 | C8H18OS | 96.000 | CCCCS(=O)CCCC | 25g | 480102057
n-Butyl sulfoxide | Oakwood Chemicals | 2168-93-6 | MFCD00002093 | 162.290 | C8H18OS | 96.000 | CCCCS(=O)CCCC | 25g | 480102057
Medchemexpress LLC Dnl343 Solution 10Mm 1Ml Dmso | HY149555-10MM 1ML DMSO
Dnl343 Solution 10Mm 1Ml Dmso
Apexbio Technology LLC MDL 28170 88191-84-8 10mM (in 1mL DMSO)
MDL 28170 (CAS 88191-84-8) is a selective inhibitor of calpain and cathepsin B with Ki values of approximately 10 nM and 25 nM respectively It acts by directly blocking the catalytic site of these cysteine proteases without inhibiting serine proteases MDL 28170 readily penetrates the blood-brain barrier inhibiting protease activity in brain tissue and mitigating ischemia-induced neurological damage in animal models The compound reduces muscle fiber sensitivity to calcium influx post-ischemia and limits myocardial injury caused by calcium overload It also exhibits antiparasitic activity in vitro significantly lowering Trypanosoma cruzi survival in infected macrophages MDL 28170 is used in biomedical research to study protease-related pathology ischemic injury and parasite-host interactions
Apexbio Technology LLC LMK 235 1418033-25-6 10mM (in 1mL DMSO)
LMK 235 (CAS 1418033-25-6) is a histone deacetylase (HDAC) inhibitor exhibiting preferential selectivity against HDAC4 and HDAC5 isoforms HDAC enzymes (EC 3 5 1 98) catalyze the removal of acetyl groups from lysine residues on histone proteins influencing DNA-histone interactions and gene expression In vitro LMK 235 demonstrates potent inhibition at nanomolar concentrations against HDAC4/5 and notable cytotoxic effects toward multiple cancer cell lines including A2780 Cal27 Kyse510 and MDA-MB231 In animal studies LMK 235 enhances the antitumor efficacy of cytarabine suggesting applications in overcoming chemoresistance in leukemia models Currently LMK 235 remains under preclinical investigation
Apexbio Technology LLC LY2835219 1231930-82-7 10mM (in 1mL DMSO)
LY2835219 (CAS 1231930-82-7) is a selective orally bioavailable inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) It targets CDK4 and CDK6 with reported IC50 values of 2 nM and 10 nM respectively thereby reducing phosphorylation of the retinoblastoma protein (Rb) This mechanism leads to cell-cycle arrest during the G1 phase and subsequent inhibition of tumor cell proliferation LY2835219 demonstrates the capacity to cross the blood-brain barrier indicating its potential utility in research involving primary or metastatic intracranial tumors
Apexbio Technology LLC WZ4002 1213269-23-8 10mM (in 1mL DMSO)
WZ4002 (CAS 1213269-23-8) is an irreversible EGFR tyrosine kinase inhibitor that selectively targets mutant epidermal growth factor receptor (EGFR) variants It potently inhibits autophosphorylation of EGFR mutants including T790M L858R/T790M delE746 A750/T790M L858R and delE746 A750 at low nanomolar Ki values Compared to wild-type EGFR mutant EGFR demonstrates greater sensitivity to WZ4002 at lower concentrations limiting off-target toxicity in normal tissues WZ4002 serves as a research tool for studying EGFR-driven tumorigenesis and therapeutic resistance in oncology models
Medchemexpress LLC Deg-77 10Mm 1Ml /Dmso Solution | HY-157334-10MM 1ML SOLUTN
Deg-77 10Mm 1Ml /Dmso Solution
Apexbio Technology LLC Vorapaxar 618385-01-6 10mM (in 1mL DMSO)
Vorapaxar (CAS 618385-01-6) is a selective inhibitor of protease-activated receptor 1 (PAR1) a G-protein coupled receptor activated by thrombin-mediated cleavage on platelet surfaces leading to platelet activation Derived from the natural product himbacine vorapaxar directly binds PAR1 inhibiting platelet aggregation induced by thrombin receptor-activating peptides (IC 25 nM) and thrombin itself (IC 47 nM) In phase III clinical trials in patients daily oral administration reduced the incidence of cardiovascular death or ischemic events highlighting its relevance as an antithrombotic research agent
Apexbio Technology LLC Nitrendipine 39562-70-4 10mM (in 1mL DMSO)
Nitrendipine (CAS number 39562-70-4) is a dihydropyridine derivative acting as a calcium channel antagonist that selectively inhibits L-type calcium channels By blocking calcium ion influx into vascular smooth muscle cells nitrendipine induces vasodilation and reduces peripheral vascular resistance thereby lowering arterial blood pressure Due to its vascular-selective calcium antagonism it serves as a pharmacological tool in cardiovascular research particularly for studying mechanisms of hypertension and calcium-dependent signaling pathways
Apexbio Technology LLC PD318088 391210-00-7 10mM (in 1mL DMSO)
PD318088 (CAS 391210-00-7) is an allosteric non-ATP competitive inhibitor of MEK1/2 kinase activity Structurally related to PD184352 it interacts adjacent to the ATP-binding site of MEK1 in proximity to residues Ile216 Phe209 Arg189 and Asp190 stabilizing a ternary complex involving MEK1/2 and MgATP This binding moderately increases the dissociation constant (Kd) for the MEK dimerization state from 75 nM to 140 nM PD318088 is mainly utilized as a molecular tool in protein kinase signaling research particularly in pathways involving MEK1/2
Apexbio Technology LLC Cyclophosphamide monohydrate 6055-19-2 10mM (in 1mL DMSO)
Cyclophosphamide monohydrate is an alkylating cytotoxic agent exhibiting antitumor activity primarily via metabolic activation As a prodrug it undergoes hepatic biotransformation mediated by cytochrome P450 enzymes forming active alkylating metabolites such as 4-hydroxycyclophosphamide which exert cytotoxic effects through interactions with cellular DNA Cyclophosphamide also reversibly inhibits acetylcholinesterase (AChE) displaying an IC50 of approximately 511 M It is widely utilized in experimental cancer studies particularly in pediatric oncology where alterations in drug metabolism or drug-drug interactions impacting cyclophosphamide clearance and therapeutic outcomes have been explored
Apexbio Technology LLC Cyclophosphamide 50-18-0 10mM (in 1mL DMSO)
Cyclophosphamide is a nitrogen mustard alkylating prodrug activated via hepatic enzymes to its active metabolites These metabolites alkylate DNA primarily at guanine residues resulting in DNA cross-linking strand breaks and mutations consequently triggering cytotoxic effects Cyclophosphamide exhibits cytotoxicity in vitro with an IC50 of 37 6 M in mouse embryo BALB/c 3T3 cells and an IC50 of 8 79 M against human HL60 cells It impacts immune regulation by decreasing regulatory T cell counts and suppressive marker expression (FoxP3 GITR) facilitating immune response modulation Commonly applied in cancer and immunological research cyclophosphamide is also employed in genotoxicity assays due to its capacity to induce chromosomal aberrations and mutations
Apexbio Technology LLC Indirubin 479-41-4 10mM (in 1mL DMSO)
Indirubin (CAS 479-41-4) is a small molecule isolated from Danggui Longhui Wan a herbal medicine formulation It exerts anti-inflammatory effects primarily through the inhibition of interferon-gamma (IFN- ) production In vitro studies demonstrated that Indirubin suppresses IFN- secretion in human bone marrow mononuclear cells (HBL-38) and murine splenocytes without affecting cell proliferation In vivo administration of Indirubin reduced ear swelling in a mouse model of 2 4 6-trinitro-1-chlorobenzene (TNCB)-induced delayed-type hypersensitivity concomitant with decreased IFN- levels in lymphocyte cultures Indirubin is under clinical investigation for conditions such as psoriasis and acute promyelocytic leukemia
Apexbio Technology LLC Pomalidomide (CC-4047) 19171-19-8 10mM (in 1mL DMSO)
Pomalidomide (CC-4047) an immunomodulatory derivative structurally related to Thalidomide exhibits anti-tumor and anti-angiogenic properties Chemically the molecule is distinguished by additional amino substituent at the fourth position of the phthalimide ring and two extra oxy groups Its mechanism of action includes modulation of specific cytokines within the tumor microenvironment (TNF- IL-6 IL-8 VEGF) suppression of tumor cell proliferation and modification of host immune cell activity Pomalidomide is widely studied in biomedical research particularly in therapeutic exploration for hematologic malignancies such as multiple myeloma including relapsed or refractory disease states